News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xenotech Introduces CryostaX(TM), an Innovative Single-Freeze Source for Human Hepatocytes


12/21/2009 1:20:28 PM

LENEXA, KS--(Marketwire - December 21, 2009) - XenoTech L.L.C., specialists in evaluation of drug candidates in vitro, is proud to introduce the latest innovation in the field of cryopreserved pooled human hepatocytes: CryostaX™.

CryostaX™ is the largest single-freeze pool of cryopreserved human hepatocytes. This patent-pending single-freeze product offers large lots of hepatocytes that allow long-term predictable results. Like all of the XenoTech products, CryostaX™ undergoes a thorough data review to ensure a dependable, high-quality source of human hepatocytes -- an integral part of any drug development program.

"CryostaX™ is an example of our continuous commitment to provide the best products to advance in vitro drug development research," said Andrew Parkinson, XenoTech's CEO/Chief Scientific Officer.

XenoTech L.L.C. is a Contract Research Organization with years of expertise in optimizing in vitro test systems and study designs to meet the ever-changing demands of scientific achievement.

"We're committed to producing high quality scientific tools that provide great value for pharmaceutical researchers," said Parkinson. "In addition to quality and value offered today, CryostaX™ allows for future customization of pooled human hepatocytes for the in-depth pursuit of safe drug candidates."

About XenoTech L.L.C.

XenoTech, founded by Dr. Andrew Parkinson in 1994, is a Contract Research Organization with unparalleled experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes. The Company offers a variety of in vitro contract studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism research. XenoTech's product selection includes a wide range of high-quality in vitro test systems, from subcellular fractions and hepatocytes to recombinant enzymes and transporter membranes. The Company can also prepare and deliver custom-designed products and services in response to client requests. XenoTech is based in Lenexa, Kansas, U.S.A. and is a division of Sekisui Medical Company. For additional information, please email info@xenotechllc.com or refer to the company's web site at www.xenotechllc.com.


For More Information Contact:
XenoTech L.L.C.
info@xenotechllc.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES